CW February 2004
Volume 13Issue Number 2 February 2004 ISSN 10593802 Fulvestrant as Second-Line Treatment for Metastatic Breast CancerWhen hormone-sensitive metastatic breast cancer progresses or recurs in postmenopausal women taking tamoxifen, fulvestrant (Faslodex, AstraZeneca) is a valuable second-line treatment option. In a clinical trial comparing fulvestrant with the third-generation aromatase inhibitor anastrozole (Arimidex, AstraZeneca), survival was similar between the two agents, according to John E. Pippen, Baylor-Sammons Cancer Center, Dallas, TX.
Go to Previous Page Go to Next Page Source & Additional Reading J. E. Pippen, 26th Annual San Antonio Breast Cancer Symposium. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
